AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10912845 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-imaging device (Walker-Sonix UBA575+)
Number of subjects: 423
Study 8765259 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate 150 mg every 3 months
Number of subjects: 80
Study 8765259 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (ethinyl estradiol 0.02 mg, desogestrel 0.15 mg) combined with oral danazol 50 mg a day for 21 days of each 28‐day cycle
Number of subjects: 80
Study 8765259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 8765259 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive plus danazol
Number of subjects: 80
Study 1389821 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed infusions of propofol and alfentanil
Number of subjects: 40
Study 1389821 — intervention group
Group type: COMPARATOR
Intervention: Separate infusions of propofol and alfentanil
Number of subjects: 40
Study 6698659 — intervention group
Group type: COMPARATOR
Intervention: Mepindolol sulfate 2 X 2.5 mg daily
Number of subjects: 6
Study 30724033 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude writing
Number of subjects: 336
Study 30724033 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude writing toward someone important
Number of subjects: 336
Study 30724033 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude writing toward someone important (Study 3)
Number of subjects: 336
Study 30724033 — intervention group
Group type: COMPARATOR
Intervention: Gratitude writing toward own health (Study 3)
Number of subjects: 336
Study 28929168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80-mg every 4 weeks)
Number of subjects: 0
Study 28929168 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to ixekizumab at Week 12)
Number of subjects: 0
Study 28929168 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (switched to ixekizumab at Week 12)
Number of subjects: 0
Study 27876027 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesogenic risk assessment and personalized feedback on mealtime routines
Number of subjects: 107
Study 27876027 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive feeding curriculum, parenting curriculum, portion size guidance, obesogenic risk assessment, personalized feedback on mealtime routines, feeding curriculum counseling, goal setting, mobile messaging, and social support
Number of subjects: 107
Study 27876027 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support component
Number of subjects: 107
Study 24617961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) administered via telemedicine, 10 weekly therapy sessions
Number of subjects: 18
Study 24617961 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine treatment
Number of subjects: 18
Study 24617961 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face therapy
Number of subjects: 18
Study 24308672 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA-250 group (TXA 250 mg)
Number of subjects: 135
Study 24308672 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA-500 group (TXA 500 mg)
Number of subjects: 135
Study 24308672 — intervention group
Group type: COMPARATOR
Intervention: Control group (physiologic saline)
Number of subjects: 135
Study 20692282 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling using motivational interviewing techniques for 6 months
Number of subjects: 0
Study 19000558 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation containing 1,000 mg levetiracetam
Number of subjects: 18
Study 19000558 — intervention group
Group type: COMPARATOR
Intervention: Control formulation (not explicitly named) containing 1,000 mg levetiracetam
Number of subjects: 18
Study 15902986 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triacylglycerol (MCT) ingestion
Number of subjects: 8
Study 15902986 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO) ingestion
Number of subjects: 8
Study 15902986 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT ingestion
Number of subjects: 8
Study 15902986 — intervention group
Group type: COMPARATOR
Intervention: CHO ingestion
Number of subjects: 8
Study 12915650 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM/EE (180-250 microg of norgestimate and 35 microg of ethinyl estradiol)
Number of subjects: 45
Study 12915650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10333196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.d. plus azithromycin 500 mg o.d. and tinidazole 500 mg b.i.d. (LAT)
Number of subjects: 70
Study 10333196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg o.d. plus azithromycin 500 mg o.d. and tinidazole 500 mg b.i.d. (PAT)
Number of subjects: 70
Study 7723896 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn sulfate (100 mg/day p.o.)
Number of subjects: 20
Study 7723896 — intervention group
Group type: COMPARATOR
Intervention: Diiodohydroxyquinolein (DQ) (80 mg/day p.o.)
Number of subjects: 20
Study 7723896 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn sulfate plus DQ (100 mg/day Zn sulfate and 80 mg/day DQ p.o.)
Number of subjects: 20
Study 7723896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2257740 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-size Mahua Ring
Number of subjects: 800
Study 2257740 — intervention group
Group type: COMPARATOR
Intervention: One-size Mahua Ring
Number of subjects: 800
Study 366146 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 31198144 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1 (55 mL iodinated contrast media)
Number of subjects: 92
Study 31198144 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2 (60 mL iodinated contrast media)
Number of subjects: 92
Study 26917198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (2g 24h and 2h before surgery, 1g twice a day for five days after surgery)
Number of subjects: 105
Study 26917198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ascorbic acid supplementation)
Number of subjects: 105
Study 26917198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 105
Study 26917198 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 26501105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 1578
Study 26501105 — intervention group
Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 1578
Study 23922179 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg for men, 0.75 g/kg for women)
Number of subjects: 15
Study 23922179 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 15
Study 23922179 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 21288119 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management (optional treatment module for ADHD)
Number of subjects: 96
Study 21288119 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial interventions
Number of subjects: 96
Study 19675535 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 29
Study 19675535 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 29
Study 16915363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 81
Study 16915363 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 81
Study 15615000 — intervention group
Group type: EXPERIMENTAL
Intervention: PST-based language model for text generation from Taiwanese Sign Language
Number of subjects: 10
Study 10604344 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback enhanced pelvic floor exercises
Number of subjects: 30
Study 10604344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback)
Number of subjects: 30
Study 9054843 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (ASA)
Number of subjects: 801
Study 9054843 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ticlopidine and aspirin (TIC-ASA)
Number of subjects: 801
Study 7683702 — intervention group
Group type: COMPARATOR
Intervention: risperidone (2 mg/day)
Number of subjects: 135
Study 7683702 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (6 mg/day)
Number of subjects: 135
Study 7683702 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (6-16 mg/day)
Number of subjects: 135
Study 7683702 — intervention group
Group type: COMPARATOR
Intervention: haloperidol (20 mg/day)
Number of subjects: 135
Study 7683702 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 135
Study 7683702 — intervention group
Group type: COMPARATOR
Intervention: risperidone (2, 6, and 16 mg/day)
Number of subjects: 135
Study 3727918 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 300 mg/day
Number of subjects: 31
Study 3727918 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg/day
Number of subjects: 31
Study 3727918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 29803590 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation with the Paradise system (ReCor Medical, Palo Alto, CA, USA)
Number of subjects: 146
Study 29803590 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (renal angiography only)
Number of subjects: 146
Study 29803590 — intervention group
Group type: COMPARATOR
Intervention: Comparison between renal denervation and sham procedure
Number of subjects: 146
Study 29803590 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 146
Study 27082709 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 50
Study 27082709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25028657 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (OCT)
Number of subjects: 338
Study 25028657 — intervention group
Group type: COMPARATOR
Intervention: Standard automated perimetry (SAP)
Number of subjects: 338
Study 25028657 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripapillary retinal nerve fiber layer (RNFL) thickness measured with Cirrus OCT
Number of subjects: 338
Study 25028657 — intervention group
Group type: COMPARATOR
Intervention: Healthy group
Number of subjects: 338
Study 21750964 — intervention group
Group type: EXPERIMENTAL
Intervention: AT→CMF
Number of subjects: 0
Study 21750964 — intervention group
Group type: EXPERIMENTAL
Intervention: AT→CMX
Number of subjects: 0
Study 21750964 — intervention group
Group type: EXPERIMENTAL
Intervention: AC→TX
Number of subjects: 0
Study 21750964 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (X) in AT→CMX
Number of subjects: 0
Study 21750964 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rates (ORR)
Number of subjects: 0
Study 21750964 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 0
Study 21750964 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study 20936190 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training of facial mimic muscles
Number of subjects: 92
Study 20936190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no functional training)
Number of subjects: 92
Study 18094668 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 32
Study 18094668 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 32
Study 18094668 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study 16205449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20-40 mg daily)
Number of subjects: 170
Study 16205449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 12434282 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 26
Study 12434282 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Number of subjects: 26
Study 12434282 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 and 10 mg)
Number of subjects: 26
Study 10507380 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (1-week course)
Number of subjects: 132
Study 10507380 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (1-month course)
Number of subjects: 132
Study 10507380 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (6-month course)
Number of subjects: 132
Study 8921100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone alone (P group)
Number of subjects: 176
Study 8921100 — intervention group
Group type: COMPARATOR
Intervention: Combination of vaginal progesterone and human chorionic gonadotrophin (P/HCG group)
Number of subjects: 176
Study 1669237 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmics
Number of subjects: 0
Study 1669237 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 6981163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose trimethoprim (TMP)
Number of subjects: 60
Study 6981163 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 60
Study 6981163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin macrocrystals
Number of subjects: 60
Study 6981163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31676642 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week interactive, family-based lifestyle intervention followed by four maintenance sessions
Number of subjects: 186
Study 31676642 — intervention group
Group type: COMPARATOR
Intervention: Modified programme with the same 10-week sessions in the family portal and four group sessions
Number of subjects: 186
Study 28819067 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT-IORT
Number of subjects: 0
Study 28819067 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 0
Study 27259315 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.75%) with 5 μg mL(‐1) of adrenaline, injected at T 8‐9 interspace, dosage: 1.8 mg kg(‐1), duration: 1.5 min
Number of subjects: 20
Study 27259315 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.75%) in patients with liver dysfunction
Number of subjects: 20
Study 27259315 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal liver function)
Number of subjects: 20
Study 23880403 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated weightbearing (AR) protocol
Number of subjects: 28
Study 23880403 — intervention group
Group type: COMPARATOR
Intervention: Current best practice (CR) weightbearing regimen
Number of subjects: 28
Study 21825934 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic inferior vena cava filter (pIVCF) placement
Number of subjects: 38
Study 21825934 — intervention group
Group type: COMPARATOR
Intervention: No pIVCF
Number of subjects: 38
Study 19857635 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptive lifestyle advice
Number of subjects: 203
Study 19857635 — intervention group
Group type: COMPARATOR
Intervention: General lifestyle advice
Number of subjects: 203
Study 16207382 — intervention group
Group type: EXPERIMENTAL
Intervention: DGIP (Dutch EASYcare Study Geriatric Intervention Programme)
Number of subjects: 151
Study 16207382 — intervention group
Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 151
Study 12870723 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 20
Study 12870723 — intervention group
Group type: COMPARATOR
Intervention: Control (no corticosteroids)
Number of subjects: 20
Study 10478769 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 77
Study 10478769 — intervention group
Group type: COMPARATOR
Intervention: Needle acupuncture
Number of subjects: 77
Study 10478769 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory medication (tenoxicam with ranitidine)
Number of subjects: 77
Study 9592305 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 800 mg at bedtime + teprenone 50 mg thrice daily
Number of subjects: 106
Study 9592305 — intervention group
Group type: COMPARATOR
Intervention: cimetidine 800 mg at bedtime alone
Number of subjects: 106
Study 9592305 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine + teprenone
Number of subjects: 106
Study 9592305 — intervention group
Group type: COMPARATOR
Intervention: cimetidine alone
Number of subjects: 106
Study 1888587 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hexetidine mouthwash
Number of subjects: 40
Study 1888587 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 40
Study 1888587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 6631327 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-contingent reward condition (tutors promised a toy if the first-grader learned all problems)
Number of subjects: 96
Study 6631327 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingent reward condition (tutors promised a toy for teaching)
Number of subjects: 96
Study 6631327 — intervention group
Group type: COMPARATOR
Intervention: No reward condition (tutors taught without promise of a toy)
Number of subjects: 96
Study 30817591 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine + 5 μg Dex
Number of subjects: 90
Study 30817591 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine + saline (Control)
Number of subjects: 90
Study 28049525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition therapy and high intensity interval training
Number of subjects: 116
Study 28049525 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study 27553436 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree model for predicting outcomes based on head AIS severity, Marshall CT score, and pupillary reactivity.
Number of subjects: 0
Study 27553436 — intervention group
Group type: COMPARATOR
Intervention: Comparison to two previously published and validated models.
Number of subjects: 0
Study 24597755 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 4051
Study 24597755 — intervention group
Group type: COMPARATOR
Intervention: All other oral antipsychotics
Number of subjects: 4051
Study 23439942 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of natural honey
Number of subjects: 60
Study 23439942 — intervention group
Group type: COMPARATOR
Intervention: Topical application of 0.15% benzydamine hydrochloride
Number of subjects: 60
Study 23439942 — intervention group
Group type: COMPARATOR
Intervention: Topical application of 0.9% normal saline
Number of subjects: 60
Study 19047319 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox
Number of subjects: 11
Study 19047319 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 11
Study 19047319 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox at isotime
Number of subjects: 11
Study 19047319 — intervention group
Group type: COMPARATOR
Intervention: Room air at isotime
Number of subjects: 11
Study 17174572 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual delineation of hippocampal atrophy rates
Number of subjects: 18
Study 17174572 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional fluid registration (forward) of hippocampal atrophy rates
Number of subjects: 18
Study 17174572 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional fluid registration (backward) of hippocampal atrophy rates
Number of subjects: 18
Study 16372792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg twice daily
Number of subjects: 100
Study 16372792 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib 60 mg twice daily
Number of subjects: 100
Study 11961179 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg bid
Number of subjects: 10
Study 11961179 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg bid
Number of subjects: 10
Study 9584497 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation of 1000 mg/day
Number of subjects: 0
Study 9584497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7619973 — intervention group
Group type: EXPERIMENTAL
Intervention: metaCPP
Number of subjects: 18
Study 7619973 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 2137322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoconazole therapy
Number of subjects: 0
Study 2137322 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (unaffected controls)
Number of subjects: 0
Study 861118 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 3 mg/kg
Number of subjects: 77
Study 861118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg/kg
Number of subjects: 77
Study 31748505 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg CBDV
Number of subjects: 34
Study 31748505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 28430718 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Collaborative Care (TCC) program
Number of subjects: 95
Study 25351456 — intervention group
Group type: EXPERIMENTAL
Intervention: anamorelin HCl
Number of subjects: 477
Study 25351456 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 477
Study 24029559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 41
Study 24029559 — intervention group
Group type: COMPARATOR
Intervention: Health education (Healthy Topics - HT)
Number of subjects: 41
Study 21729832 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1002
Study 21729832 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1002
Study 18722479 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Cue Single task (CCS)
Number of subjects: 40
Study 18722479 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Cue Dual task (CCD)
Number of subjects: 40
Study 18722479 — intervention group
Group type: COMPARATOR
Intervention: No Cue (NC)
Number of subjects: 40